ReviewImmunologic research2011
Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.
Review in Immunologic research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 3 syntheses or guidelines pooled it, 284 citations in OpenAlex.
- The pertinence of gastric cancer and interleukin 10-819 single nucleotide polymorphisms: a meta-analysis and systematic review.BMC gastroenterology · 2024Pooled it
- Pooled it
- Effectiveness of Acupuncture and Moxibustion for Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing Standard Treatment: A Systematic Review and Meta-Analysis.Integrative cancer therapiesPooled it
- DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment.PloS one · 2016Trial
- Trial
- The Impact of SF3B1 Mutations on the Tumor Microenvironment and Response to Immunotherapy.Cancer medicine · 2026Article
- Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy.Molecular therapy. Oncology · 2026Article
- Engineered macrophages with IL-10-TLR9 signal switch receptors for reprogramming tumor microenvironment and enhancing antitumor immunity.Experimental & molecular medicine · 2026Article
- Vitamin D delivered through carbon quantum dots modifies cytokine expression and migration in MCF-7 breast cancer cells.Molecular biology reports · 2026Article
- Circulating cell populations as response predictors and targets to improve immunotherapy in metastatic lung cancer.iScience · 2026Article
- A next-generation multimetal complex induces immunogenic cell death with distinct transcriptomic signatures.Chemical communications (Cambridge, England) · 2026Article
- Glucose metabolic reprogramming as a driver of immunosuppression in the tumour microenvironment.Clinical and translational medicine · 2026Review
- Enhancing nanomedicine efficacy in KPC pancreatic tumors through ketotifen-mediated tumor microenvironment remodeling.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Modulatory role of Akkermansia muciniphila in cancer pathophysiology: a systematic review and meta-analysis of preclinical studies.Gut pathogens · 2026Review
- Lung tissue-resident memory T cells optimize protection by IL-10 regulation of innate immunity.The Journal of experimental medicine · 2026Article
- Conversion of natural cytokine receptors into orthogonal synthetic biosensors.Nature chemical biology · 2025Article
- Anti-tumor and immunomodulatory activity of Ganoderma parvulum-derived polysaccharides.Bioscience reports · 2025Article
- The Tumor Environment in Peritoneal Carcinomatosis and Malignant Pleural Effusions: Implications for Therapy.Cancers · 2025Review
- Tumor-Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies.Children (Basel, Switzerland) · 2025Review
- Roles of benefit finding in psychological and inflammatory adjustments in persons with colorectal cancer: a prospective analysis on the multidimensionality of benefit finding.Psychology & health · 2025Article
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-10 is an immunomodulatory cytokine that is frequently upregulated in various types of cancer. The biological role of IL-10 in cancer is quite complex; however, the presence of IL-10 in advanced metastases and the positive correlation between serum IL-10 levels and progression of disease indicates a critical role of IL-10 in the tumor microenvironment. IL-10 has been shown to directly affect the function of antigen-presenting cells by inhibiting the expression of MHC and costimulatory molecules, which in turn induces immune suppression or tolerance. Additionally, IL-10 downregulates the expression of Th1 cytokines and induces T-regulatory responses. Taken together, a combination of IL-10 antagonism and immunostimulatory treatments such as cancer vaccines, Toll-like receptor agonists, Th1 cytokines, and chemokines would be a logical approach to enhance an antitumor immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.